Resources from the same session
603O - First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
Presenter: Robin Guo
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
612O - Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
Presenter: Maria Vieito
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 603O and 612O
Presenter: Christophe Le Tourneau
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Webcast
605O - YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
Presenter: Hongyun Zhao
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
606O - Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Presenter: Funda Meric-Bernstam
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
607O - Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
Presenter: Marc Oliva Bernal
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 605O, 606O and 607O
Presenter: Lillian Siu
Session: Proffered paper session 1: Developmental therapeutics
Resources:
Slides
Webcast